mTeSR™1
cGMP, feeder-free maintenance medium for human ES and iPS cells
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
Overview
mTeSR™1, now manufactured under cGMP, is the most widely published feeder-free cell culture medium for human embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells), with established protocols for applications ranging from derivation to differentiation. It has been used to successfully maintain thousands of ES and iPS cell lines in over 50 countries, and has supported top pluripotent stem cell publications and researchers. mTeSR™1 is a highly specialized, serum-free and complete cell culture medium. With pre-screened raw materials that ensure batch-to-batch consistency and robust feeder-free protocols for ES and iPS cell culture, mTeSR™1 provides more consistent cultures with homogeneous, undifferentiated phenotypes.
mTeSR™1 is manufactured under relevant cGMPs, ensuring the highest quality and consistency for reproducible results.
To request a Letter of Authorization (LOA) for mTeSR’s Drug Master File, click here.
mTeSR™1 is manufactured under relevant cGMPs, ensuring the highest quality and consistency for reproducible results.
To request a Letter of Authorization (LOA) for mTeSR’s Drug Master File, click here.
Components
- mTeSR™1 Complete Kit (Catalog #85850)
- mTeSR™1 Basal Medium, 400 mL
- mTeSR™1 5X Supplement, 100 mL
- mTeSR™1 Complete Kit, 1 L (Catalog #85857)
- mTeSR™1 Basal Medium, 800 mL
- mTeSR™1 5X Supplement, 100 mL, 2 Bottles
- mTeSR™1 Complete Kit, 10 Pack (Catalog #85870)
- mTeSR™1 Basal Medium, 400 mL, 10 Bottles
- mTeSR™1 5X Supplement, 100 mL, 10 Bottles
- mTeSR™1 Complete Kit, 25 Pack (Catalog #85875)
- mTeSR™1 Basal Medium, 400 mL, 25 Bottles
- mTeSR™1 5X Supplement, 100 mL, 25 Bottles
Subtype
Specialized Media
Cell Type
Pluripotent Stem Cells
Species
Human
Application
Cell Culture, Expansion, Maintenance
Brand
TeSR
Area of Interest
Stem Cell Biology
Formulation
Serum-Free
Related Products
Related Products
Scientific Resources
Product Documentation
| Document Type | Product Name | Catalog # | Lot # | Language |
|---|---|---|---|---|
|
Document Type
Product Information Sheet
|
Product Name
mTeSR™1
|
Catalog # 85850, 85857 |
Lot # All |
Language English |
|
Document Type
Manual
|
Product Name
mTeSR™1
|
Catalog # 85850 |
Lot # All |
Language English |
|
Document Type
Safety Data Sheet 1
|
Product Name
mTeSR™1
|
Catalog # 85850 |
Lot # All |
Language English |
|
Document Type
Safety Data Sheet 2
|
Product Name
mTeSR™1
|
Catalog # 85850 |
Lot # All |
Language English |
|
Document Type
Safety Data Sheet 3
|
Product Name
mTeSR™1
|
Catalog # 85850 |
Lot # All |
Language English |
Educational Materials(40)
Brochure
cGMP mTeSR™1
Brochure
Maximize Your Pluripotential with the TeSR™ Family of hPSC Culture Media
Brochure
qPCR Arrays for Cell Characterization
Brochure
Products for Human Pluripotent Stem Cells
Brochure
2019-2020 Cell Culture Training Catalog
Brochure
mTeSR™3D Suspension Culture Medium for hPSCs
Technical Bulletin
Weekend-Free Culture of Human Pluripotent Stem Cells in mTeSR™1 or TeSR™-E8™
Wallchart
Stem Cell States: Naive to Primed Pluripotency
Wallchart
Derivation and Applications of Human Pluripotent Stem Cells
Wallchart
Directed Differentiation of Pluripotent Stem Cells
Wallchart
Pluripotent Stem Cell Biology
Video
28:45
STEMCELL Journal Club: Cerebral Organoids for Human-Specific Infection Modeling
Video
8:33
How to Set Up an Assay with the hPSC Genetic Analysis Kit Experiment
Video
1:45
mTeSR™1: The Most Published, Feeder-Independent hESC & hiPSC Maintenance Medium
Video
9:18
How to Grow Cerebral Organoids from Human Pluripotent Stem Cells
Video
1:27
mTeSR™1: Standardized Medium for the Feeder-Independent Maintenance of hESCs & hiPSCs
Video
3:39
How to Count hPSC Aggregates to Determine Plating Density for Maintenance and Differentiation
Video
3:10
Limitless Potential: Do More with TeSR™
Video
5:58
A Guide to Passaging Human Pluripotent Stem Cells Using mTeSR™1
Webinar
21:35
Nature Research Round Table: Regulations Around Human Induced Pluripotent Stem Cell Registration
Webinar
42:10
Development, Compatibility, and Applications of mTeSR™ Plus; an Enhanced Medium for the Maintenance of Human Pluripotent Stem Cells (hPSCs)
Webinar
1:02:03
Building Brain Organoids and Assembloids to Study Human Development and Disease
Webinar
47:18
Madeline Lancaster on Brain Organoids: Modeling Human Brain Development in a Dish
Webinar
29:03
Nature Research Round Table: hPSC Lines for Cell Therapies - Panel Discussion
Webinar
49:25
Investigating Metabolic Disease with Human Pluripotent Stem Cells
Webinar
19:35
Nature Research Round Table: Retinal Cell Therapy Using Human Embryonic Stem Cells
Webinar
13:01
Nature Research Round Table: HLA Typing Considerations for Human Pluripotent Stem Cell Banking
Webinar
1:07:14
Optimized Workflows for High-Efficiency Genome Editing in Stem and Primary Cell Types
Webinar
55:53
Maintaining and Assessing High-Quality hPSC Cultures
Webinar
1:13:44
Quality Control Guidelines for Clinical-Grade Human Induced Pluripotent Stem Cell Lines
Webinar
53:35
Whole Exome Sequencing Reveals Selective Pressures and Dominant Negative Mutations in hPSC Cultures
Webinar
24:46
Nature Research Round Table: Parkinson's Disease Therapy with Human Embryonic Stem Cells
Webinar
13:02
Nature Research Round Table: Standards for Pluripotent Stem Cell Banking
Webinar
20:09
Nature Research Round Table: Maintenance of Human Pluripotent Stem Cells In Vitro
Webinar
50:49
hPSC Quality: Essential Considerations for Gene Editing, Cloning, Maintenance and Disease Modeling
Webinar
47:23
Human Pluripotent Stem Cells for the Treatment of Age-Related Macular Degeneration and Compliance Considerations for Clinical-Grade iPSCs
Webinar
25:30
Brains in a Dish: Using Cerebral Organoids to Study Human Brain Development and Disease
Webinar
17:30
Nature Research Round Table: Human Pluripotent Stem Cell Lines as Disease Models
Webinar
42:37
Genome Editing From Modeling Disease to Novel Therapeutics
Webinar
33:47
Nature Research Round Table: Defining and Maintaining Pluripotency & hPSC Line Registration and Banking - Panel Discussion
Load More Educational Materials
Product Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Research Area
Workflow Stages
Workflow Stages for
Human Pluripotent Stem Cell Research
Workflow Stages for
PSC Quality Control
Data and Publications
Data
Figure 1. Normal hES and hiPS Cell Morphology is Observed in cGMP mTeSR™1 Cultures
Undifferentiated (A) H1 human embryonic stem (hES) and (B) WLS-1C human induced pluripotent stem (hiPS) cells cultured on Corning® Matrigel® Matrix in cGMP mTeSR™1 retain the prominent nucleoli and high nuclear-to-cytoplasmic ratio characteristic of this cell type after 10 passages. Densely packed cells and multi-layering are prominent when cells are ready to be passaged.
Figure 2. High Expansion Rates are Observed in cGMP mTeSR™1 Cultures
Graph shows the average fold expansion per passage +/- SEM obtained for hES (H1 and H9) and hiPS (WLS-1C) cells cultured in cGMP mTeSR™1 (red) or non-cGMP mTeSR™1 (gray) on Corning® Matrigel® Matrix over 10 passages. Expansion was determined by enumerating the cell aggregates obtained at harvest and dividing by the number of cell aggregates seeded. Note that this data is representative of cultures passaged after 6-7 days in culture, lower expansion should be expected if using shorter culture times.
Figure 3. Cells Cultured in cGMP mTeSR™1 Medium Express Undifferentiated Cell Markers
Histogram analysis for hES (H1 and H9) and hiPS (WLS-1C) cells characterized using FACS for undifferentiated cell markers, OCT4 (OCT3) (Catalog #60093) and TRA-1-60 (Catalog #60064), after 8 - 10 passages in cGMP mTeSR™1 (filled = sample, blank = isotype control).
Figure 4. hPSCs Maintained in cGMP mTeSR™1 Display a Normal Karyotype
Karyograms of (A) H1 hES and (B) WLS-1C hiPS cells cultured in cGMP mTeSR™1 for 11 passages shows that a normal karyotype is retained.
Publications (1576)
Stem cell reports 2020 feb
iPSC-Based Modeling of RAG2 Severe Combined Immunodeficiency Reveals Multiple T Cell Developmental Arrests.
Abstract
Abstract
RAG2 severe combined immune deficiency (RAG2-SCID) is a lethal disorder caused by the absence of functional T and B cells due to a differentiation block. Here, we generated induced pluripotent stem cells (iPSCs) from a RAG2-SCID patient to study the nature of the T cell developmental blockade. We observed a strongly reduced capacity to differentiate at every investigated stage of T cell development, from early CD7-CD5- to CD4+CD8+. The impaired differentiation was accompanied by an increase in CD7-CD56+CD33+ natural killer (NK) cell-like cells. T cell receptor D rearrangements were completely absent in RAG2SCID cells, whereas the rare T cell receptor B rearrangements were likely the result of illegitimate rearrangements. Repair of RAG2 restored the capacity to induce T cell receptor rearrangements, normalized T cell development, and corrected the NK cell-like phenotype. In conclusion, we succeeded in generating an iPSC-based RAG2-SCID model, which enabled the identification of previously unrecognized disorder-related T cell developmental roadblocks.
Analytical chemistry 2020
One-Stop Microfluidic Assembly of Human Brain Organoids To Model Prenatal Cannabis Exposure.
Abstract
Abstract
Prenatal cannabis exposure (PCE) influences human brain development, but it is challenging to model PCE using animals and current cell culture techniques. Here, we developed a one-stop microfluidic platform to assemble and culture human cerebral organoids from human embryonic stem cells (hESC) to investigate the effect of PCE on early human brain development. By incorporating perfusable culture chambers, air-liquid interface, and one-stop protocol, this microfluidic platform can simplify the fabrication procedure and produce a large number of organoids (169 organoids per 3.5 cm × 3.5 cm device area) without fusion, as compared with conventional fabrication methods. These one-stop microfluidic assembled cerebral organoids not only recapitulate early human brain structure, biology, and electrophysiology but also have minimal size variation and hypoxia. Under on-chip exposure to the psychoactive cannabinoid, $\Delta$-9-tetrahydrocannabinol (THC), cerebral organoids exhibited reduced neuronal maturation, downregulation of cannabinoid receptor type 1 (CB1) receptors, and impaired neurite outgrowth. Moreover, transient on-chip THC treatment also decreased spontaneous firing in these organoids. This one-stop microfluidic technique enables a simple, scalable, and repeatable organoid culture method that can be used not only for human brain organoids but also for many other human organoids including liver, kidney, retina, and tumor organoids. This technology could be widely used in modeling brain and other organ development, developmental disorders, developmental pharmacology and toxicology, and drug screening.
Frontiers in bioengineering and biotechnology 2020
Maturation of Human Pluripotent Stem Cell-Derived Cerebellar Neurons in the Absence of Co-culture.
Abstract
Abstract
The cerebellum plays a critical role in all vertebrates, and many neurological disorders are associated with cerebellum dysfunction. A major limitation in cerebellar research has been the lack of adequate disease models. As an alternative to animal models, cerebellar neurons differentiated from pluripotent stem cells have been used. However, previous studies only produced limited amounts of Purkinje cells. Moreover, in vitro generation of Purkinje cells required co-culture systems, which may introduce unknown components to the system. Here we describe a novel differentiation strategy that uses defined medium to generate Purkinje cells, granule cells, interneurons, and deep cerebellar nuclei projection neurons, that self-formed and differentiated into electrically active cells. Using a defined basal medium optimized for neuronal cell culture, we successfully promoted the differentiation of cerebellar precursors without the need for co-culturing. We anticipate that our findings may help developing better models for the study of cerebellar dysfunctions, while providing an advance toward the development of autologous replacement strategies for treating cerebellar degenerative diseases.
Human immunology 2019 jul
Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch.
Abstract
Abstract
Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1{\%} to 5.3{\%}. Patients with native diseases considered 'immunological' (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3{\%}) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors.
Scientific reports 2019
L-type voltage-gated calcium channel regulation of in vitro human cortical neuronal networks.
Abstract
Abstract
The combination of in vitro multi-electrode arrays (MEAs) and the neuronal differentiation of stem cells offers the capability to study human neuronal networks from patient or engineered human cell lines. Here, we use MEA-based assays to probe synaptic function and network interactions of hiPSC-derived neurons. Neuronal network behaviour first emerges at approximately 30 days of culture and is driven by glutamate neurotransmission. Over a further 30 days, inhibitory GABAergic signalling shapes network behaviour into a synchronous regular pattern of burst firing activity and low activity periods. Gene mutations in L-type voltage gated calcium channel subunit genes are strongly implicated as genetic risk factors for the development of schizophrenia and bipolar disorder. We find that, although basal neuronal firing rate is unaffected, there is a dose-dependent effect of L-type voltage gated calcium channel inhibitors on synchronous firing patterns of our hiPSC-derived neural networks. This demonstrates that MEA assays have sufficient sensitivity to detect changes in patterns of neuronal interaction that may arise from hypo-function of psychiatric risk genes. Our study highlights the utility of in vitro MEA based platforms for the study of hiPSC neural network activity and their potential use in novel compound screening.
Translational psychiatry 2019
Comparative characterization of human induced pluripotent stem cells (hiPSC) derived from patients with schizophrenia and autism.
Abstract
Abstract
Human induced pluripotent stem cells (hiPSC) provide an attractive tool to study disease mechanisms of neurodevelopmental disorders such as schizophrenia. A pertinent problem is the development of hiPSC-based assays to discriminate schizophrenia (SZ) from autism spectrum disorder (ASD) models. Healthy control individuals as well as patients with SZ and ASD were examined by a panel of diagnostic tests. Subsequently, skin biopsies were taken for the generation, differentiation, and testing of hiPSC-derived neurons from all individuals. SZ and ASD neurons share a reduced capacity for cortical differentiation as shown by quantitative analysis of the synaptic marker PSD95 and neurite outgrowth. By contrast, pattern analysis of calcium signals turned out to discriminate among healthy control, schizophrenia, and autism samples. Schizophrenia neurons displayed decreased peak frequency accompanied by increased peak areas, while autism neurons showed a slight decrease in peak amplitudes. For further analysis of the schizophrenia phenotype, transcriptome analyses revealed a clear discrimination among schizophrenia, autism, and healthy controls based on differentially expressed genes. However, considerable differences were still evident among schizophrenia patients under inspection. For one individual with schizophrenia, expression analysis revealed deregulation of genes associated with the major histocompatibility complex class II (MHC class II) presentation pathway. Interestingly, antipsychotic treatment of healthy control neurons also increased MHC class II expression. In conclusion, transcriptome analysis combined with pattern analysis of calcium signals appeared as a tool to discriminate between SZ and ASD phenotypes in vitro.
Legal Statement:
This product was developed under license to intellectual property owned by WiCell™ Research Institute (patent pending). This product is sold for research use only (whether the buyer is an academic or for-profit entity) under a non-transferable, limited-use license. Purchase of this product does not include the right to sell, use or otherwise transfer this product for commercial purposes (i.e., any activity undertaken for consideration, such as use of this product for manufacturing, or resale of this product or any materials made using this product, or use of this product or any materials made using this product to provide services) or clinical use (i.e., administration of this product or any material using this product to humans) or the right to implant any material made using this product into an animal by, or in collaboration with, a for-profit entity, for purposes other than basic pre-clinical research applications (including without limitation teratoma assays) to validate the function of the cells. Purchasers wishing to use the product for purposes other than research use should contact Asterias Biotherapeutics, Inc. legal department at (650) 433-2900 or legal@asteriasbio.com. Purchasers who do not agree to the terms and conditions set forth above should return the product in acceptable conditions to the seller for a refund.
Quality Statement:
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
